What is the CJC-1295 & Ipamorelin Stack?
In preclinical endocrinology research, the combination of CJC-1295 (a GHRH analog) and Ipamorelin (a GHRP receptor agonist) is widely studied for its dual-action signaling mechanism. By targeting different receptors on the pituitary gland, these compounds work in synergy to promote natural, pulsatile growth hormone secretion.
Unlike older growth hormone secretagogues, this combination is highly selective. It stimulates growth hormone release without producing undesirable spikes in cortisol, prolactin, or aldosterone, making it a preferred model for injury recovery, muscle tissue synthesis, and body composition research.
Key Benefits Identified in Research Models
Preclinical studies indicate that the CJC-1295 and Ipamorelin stack yields significant metabolic and cellular repair benefits. These effects are mediated by increased levels of circulating IGF-1 (Insulin-like Growth Factor 1).
Key parameters observed in laboratory research include:
- Accelerated tissue recovery and wound healing via enhanced protein synthesis.
- Increased metabolic rate and adipose tissue reduction through growth-hormone-induced lipolysis.
- Mitochondrial cellular adaptation and improved sleep quality profiles in model subjects.
- Minimal impact on insulin sensitivity compared to synthetic human growth hormone (hGH).
Dosage Protocols and Reconstitution Guidelines
In scientific literature, the CJC-1295 (without DAC) and Ipamorelin combination is typically evaluated at equal ratios, such as 1:1 or 1:2. The most common stack contains 5mg of CJC-1295 and 5mg of Ipamorelin in a single vial, or co-lyophilized for reconstitution convenience.
For a standard 10mg co-lyophilized vial, researchers typically add 2.0 ml of sterile bacteriostatic water. This yields a concentration of 2.5mg (2500mcg) of each compound per ml. Dilution must be handled slowly by running the diluent down the inner glass wall, avoiding mechanical agitation, and storing the reconstituted liquid immediately at 2-8°C.